UGT2B17: A Potential Drug Target and Biomarker (G7367)

Target Name: UGT2B17

NCBI ID: G7367

UGT2B17

UGT2B17: A Potential Drug Target and Biomarker

Glucuronosyltransferase 2B17 (UGT2B17) is a gene that encodes a protein involved in the detoxification of drugs, including many types of cancer drugs. The function of UGT2B17 has been studied extensively, and its role in drug metabolism and elimination has led to its potential as a drug target or biomarker. In this article, we will explore the potential of UGT2B17 as a drug target and biomarker.

Drug Metabolism and UGT2B17

UGT2B17 is a member of the UGT family of enzymes that are responsible for the detoxification of drugs. These enzymes have been shown to play a crucial role in the metabolism of many drugs, including chemotherapy drugs, which are often used to treat cancer. One of the primary functions of UGT2B17 is to transport the drug-carrying glucose molecules to the liver for elimination.

However, UGT2B17 also has other functions that are relevant to drug metabolism. For example, it has been shown to be involved in the metabolism of some drugs that are used to treat chronic pain, such as nonsteroidal anti-inflammatory drugs (NSAIDs). UGT2B17 has also been shown to be involved in the metabolism of drugs that are used to treat depression, such as selective serotonin reuptake inhibitors (SSRIs).

Drug Inhibition and UGT2B17

The potential of UGT2B17 as a drug target comes from its ability to interact with and inhibit the activity of other enzymes involved in drug metabolism. One of the primary targets for UGT2B17 is the liver enzyme CYP2C9, which is involved in the metabolism of many drugs, including many types of cancer drugs.

Studies have shown that UGT2B17 can inhibit the activity of CYP2C9 by forming a covalent complex with the enzyme. This inhibition of CYP2C9 by UGT2B17 could lead to reduced levels of the drug in the body, which could potentially make these drugs more potent or less potent, depending on the context.

Another potential target for UGT2B17 is the brain-gene neurotrophic factor (NTF), which is involved in the survival and growth of brain cells. Studies have shown that UGT2B17 can inhibit the activity of NTF by forming a covalent complex with the protein. This inhibition of NTF by UGT2B17 could potentially lead to the loss of brain cells, which could have serious consequences for brain health.

Biomarker Potential

The potential of UGT2B17 as a biomarker comes from its ability to be measured and correlated with the efficacy of drugs. One of the primary biomarkers for drug metabolism is the area under the curve (AUC), which is a measure of the concentration of a drug in the body over time. UGT2B17 has been shown to be involved in the metabolism of many drugs, including cancer drugs, and its activity can be measured by measuring the AUC of these drugs.

In addition to AUC, UGT2B17 has been shown to be involved in other biomarkers that are relevant to drug metabolism, such as the maximum plasma concentration (MPC) and the elimination half-life (t1/2). These biomarkers can be used to monitor the effectiveness of drugs and to determine the rate of drug elimination from the body.

Conclusion

UGT2B17 is a gene that encodes a protein involved in the detoxification of drugs. Its functions in drug metabolism and elimination make it a potential drug target and biomarker. The inhibition of CYP2C9 and NTF by UGT2B17 suggests that it may be a useful target for drugs that are used to treat

Protein Name: UDP Glucuronosyltransferase Family 2 Member B17

Functions: UDP-glucuronosyltransferase (UGT) that catalyzes phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase the metabolite's water solubility, thereby facilitating excretion into either the urine or bile (PubMed:8798464, PubMed:16595710, PubMed:18719240, PubMed:19022937, PubMed:23288867). Catalyzes the glucuronidation of endogenous steroid hormones such as androgens (epitestosterone, androsterone) and estrogens (estradiol, epiestradiol) (PubMed:8798464, PubMed:16595710, PubMed:18719240, PubMed:19022937, PubMed:23288867)

The "UGT2B17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UGT2B17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets